InsiderTrades.com logo
Jason Adair net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Jason Adair Biography and Net Worth

Chief Business Officer of Liquidia

Jason Adair joined Liquidia in 2016 where he serves as Chief Business Officer. In this role, he is responsible for corporate development activities including strategy, investor relations, communications and the pursuit of collaboration and licensing opportunities for the company. Prior to joining Liquidia, Jason led business development efforts at BioCryst Pharmaceuticals as its Executive Director of Corporate Development. His work included the commercial launch and subsequent partnering of the company’s first FDA approved drug. Jason also worked at MedImmune/AstraZeneca in roles of increasing responsibility in business development, marketing and operations. Before entering the pharmaceutical industry, Jason worked as an analytical chemist for Syngenta and served as an officer in the United States Army. He holds a Master of Business Administration from the Tuck School of Business at Dartmouth College and a Bachelor of Science in Chemistry from Wake Forest University.

What is Jason Adair's net worth?

The estimated net worth of Jason Adair is at least $2.72 million as of January 27th, 2025. Mr. Adair owns 179,770 shares of Liquidia stock worth more than $2,718,122 as of March 24th. This net worth estimate does not reflect any other assets that Mr. Adair may own. Learn More about Jason Adair's net worth.

How old is Jason Adair?

Mr. Adair is currently 52 years old. There are 5 older executives and no younger executives at Liquidia. The oldest executive at Liquidia is Dr. Roger A. Jeffs Ph.D., CEO & Director, who is 62 years old. Learn More on Jason Adair's age.

How do I contact Jason Adair?

The corporate mailing address for Mr. Adair and other Liquidia executives is 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560. Liquidia can also be reached via phone at (919) 328-4400 and via email at ir@liquidia.com. Learn More on Jason Adair's contact information.

Has Jason Adair been buying or selling shares of Liquidia?

During the past quarter, Jason Adair has sold $6,319.00 in Liquidia stock. Most recently, Jason Adair sold 445 shares of the business's stock in a transaction on Monday, January 27th. The shares were sold at an average price of $14.20, for a transaction totalling $6,319.00. Following the completion of the sale, the insider now directly owns 179,770 shares of the company's stock, valued at $2,552,734. Learn More on Jason Adair's trading history.

Who are Liquidia's active insiders?

Liquidia's insider roster includes Jason Adair (Chief Business Officer), Arthur Kirsch (Director), Paul Manning (Director), Scott Moomaw (Chief Commercial Officer), and Russell Schundler (General Counsel). Learn More on Liquidia's active insiders.

Are insiders buying or selling shares of Liquidia?

In the last year, Liquidia insiders bought shares 1 times. They purchased a total of 150,000 shares worth more than $1,426,500.00. In the last year, insiders at the sold shares 31 times. They sold a total of 133,327 shares worth more than $1,616,512.79. The most recent insider tranaction occured on January, 27th when insider Jason Adair sold 445 shares worth more than $6,319.00. Insiders at Liquidia own 30.1% of the company. Learn More about insider trades at Liquidia.

Information on this page was last updated on 1/27/2025.

Jason Adair Insider Trading History at Liquidia

See Full Table

Jason Adair Buying and Selling Activity at Liquidia

This chart shows Jason Adair's buying and selling at Liquidia by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$6.32ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50k$0$50kTotal Insider BuyingTotal Insider Selling

Liquidia Company Overview

Liquidia logo
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Read More

Today's Range

Now: $15.75
Low: $15.08
High: $15.86

50 Day Range

MA: $14.79
Low: $11.36
High: $16.52

2 Week Range

Now: $15.75
Low: $8.26
High: $16.92

Volume

436,616 shs

Average Volume

932,710 shs

Market Capitalization

$1.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.07